{'52WeekChange': -0.41618496,
 'SandP52WeekChange': 0.0644362,
 'address1': '300 Park Avenue',
 'address2': '12th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.03,
 'askSize': 1300,
 'averageDailyVolume10Day': 795487,
 'averageVolume': 1573942,
 'averageVolume10days': 795487,
 'beta': None,
 'beta3Year': None,
 'bid': 1.01,
 'bidSize': 1300,
 'bookValue': 0.154,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.12,
 'dayLow': 0.9801,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': 87.23,
 'enterpriseValue': 32711404,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 1.1445714,
 'fiftyTwoWeekHigh': 1.98,
 'fiftyTwoWeekLow': 0.42,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 37926033,
 'forwardEps': -0.41,
 'forwardPE': -2.4634147,
 'fromCurrency': None,
 'fullTimeEmployees': 6,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.16237,
 'heldPercentInstitutions': 0.083330005,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1548288000,
 'lastSplitFactor': '1:30',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/seelostherapeutics.com',
 'longBusinessSummary': 'Seelos Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on developing '
                        'novel technologies and therapeutics for the treatment '
                        'of central nervous system, respiratory, and other '
                        "disorders. The company's lead programs are SLS-002, "
                        'an intranasal racemic ketamine for the treatment of '
                        'suicidality in post-traumatic stress disorder and in '
                        'depressive disorder; SLS-005, a protein stabilizer '
                        'for the treatment of Sanfilippo syndrome; and '
                        'SLS-006, a partial dopamine agonist for monotherapy '
                        "in early stage Parkinson's disease patients. Its "
                        'preclinical programs include SLS-007, an '
                        'anti-alpha-synuclein peptidic inhibitor to treat '
                        "patients with Parkinson's disease or Lewy Body "
                        'Dementia; SLS-008, an orally available antagonist for '
                        'chemoattractant receptor-homologous molecule for the '
                        'treatment of chronic inflammation in asthma and '
                        'orphan indications; SLS-010, an oral histamine H3A '
                        'receptor antagonist for narcolepsy and related '
                        'disorders; and SLS-012, an injectable therapy for '
                        'post-operative pain management. The company was '
                        'founded in 2016 and is headquartered in New York, New '
                        'York.',
 'longName': 'Seelos Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 45399400,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_402470124',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -20575000,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.12,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '646-998-6475',
 'previousClose': 1.11,
 'priceHint': 4,
 'priceToBook': 6.5584416,
 'priceToSalesTrailing12Months': 121.06506,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.12,
 'regularMarketDayLow': 0.9801,
 'regularMarketOpen': 1.12,
 'regularMarketPreviousClose': 1.11,
 'regularMarketPrice': 1.12,
 'regularMarketVolume': 1249028,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 44949900,
 'sharesPercentSharesOut': 0.0134000005,
 'sharesShort': 602655,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 985350,
 'shortName': 'Seelos Therapeutics, Inc.',
 'shortPercentOfFloat': 0.014400001,
 'shortRatio': 0.42,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'SEEL',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.773,
 'twoHundredDayAverage': 0.9238129,
 'volume': 1249028,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.seelostherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10022'}